Work

P51.01 Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)

Year: 2021

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2021.08.538

Authors: C.K. Liam, A. Rozila Ahmad, T. Hsia, J.Y. Li, X. Le, J. Heymach, J.C. Yang, R. Soo, Y. Zhang, S. Kim, S.W. Shin, A. Johne, N. Karachaliou, R. Bruns, B. Ellers-Lenz, Y. Wu

Institutions: University Malaya Medical Centre, University of Malaya, China Medical University Hospital, The University of Texas MD Anderson Cancer Center, National Taiwan University Hospital, National University Cancer Institute, Singapore, Zhejiang Cancer Hospital, Asan Medical Center, Korea University Anam Hospital, Merck KGaA, Darmstadt (Germany), Merck Healthcare KGaA, Darmstadt (Germany), Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3204974323

Cites:

Cited by:

Related to: 10